ApyraVax -Model MV-001 -Clostridioides Difficile Infection (CDI)

Clostridioides difficile infection is a world-wide serious and deadly disease. Clostridioides difficile infection (CDI) is a nosocomial, antibiotics associated infectious diarrhea characterized by a high mortality rate, in particular in people above the age of 65. Current treatments include antibiotics and fecal transplantation. Recurrence rates are 20-30% and deaths in the US over 29’000 every year. The total cost per patient is extremely high. ApyraVax is suitable for continuous dosing, exploits the already marketed and safe Salmonella Ty21a vaccine strain (Vivotif®) and induces high-affinity secretory IgAs that ensure protection from CDI.